CAR-T Therapy: Clinical Trials

12 trials of CAR-T Therapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 recruiting, 2 not yet recruiting, 1 unknown. 6 Phase 1, 3 Early Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Recruiting 4, Not yet recruiting 2
Early Phase 13Recruiting 2, Unknown 1
Phase 21Recruiting 1

Follow CAR-T Therapy: new trials by email Literature Review of CAR-T Therapy trials Research Report on CAR-T Therapy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
CAR-T Therapy - Systemic Lupus Erythematosus (SLE)
Early Phase 1RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology122026-01-162026-01-14
Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC
CAR-T Therapy - SSc-Systemic Sclerosis
Early Phase 1RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology122026-01-162026-01-21
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
CAR-T Therapy - CD7+ T-ALL/LBL
Phase 1RecruitingPeking University People's Hospital182025-08-182025-12-12
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody - Multiple Myeloma, Relapsed, Multiple Myeloma (MM)
RecruitingSung-Soo Park1742025-07-142025-07-15
Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
CAR-T Therapy - Systemic Lupus Erythematosus (SLE)
Phase 1RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology122025-07-112025-11-24
The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
CAR-T Therapy - ANCA Associated Vasculitis (AAV)
Phase 1Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology122025-07-012025-06-24
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
CAR-T Therapy - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Phase 1RecruitingBeijing GoBroad Hospital272025-02-202026-03-10
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
CAR-T Therapy - CAR-T Cell Therapy, Lymphomas
Phase 1Not yet recruitingMingzhi Zhang302024-12-012024-10-17
CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
CAR-T Therapy - Acute Lymphoblastic Leukemia
Phase 1RecruitingGuangzhou Women and Children's Medical Center102024-10-012024-12-31
Immunotherapy in Lymphoma
CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate - Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma
RecruitingSung-Soo Park722024-06-262025-01-28
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
Fecal Microbiota Transplantation, Chemotherapy, CAR-T Therapy - Lymphoma
Phase 2RecruitingM.D. Anderson Cancer Center402024-02-192026-11-12
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma
CAR-T Therapy - Peripheral T Cell Lymphoma
Early Phase 1UnknownZhao Weili352023-09-012023-08-21

Conditions studied

Lupus Erythematosus, Systemic (3)  ·  Lymphoma (3)  ·  Recurrence (3)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1)  ·  Burkitt Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, T-Cell, Peripheral (1)  ·  Multiple Myeloma (1)  ·  Neoplasm, Residual (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Scleroderma, Systemic (1)

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (4)  ·  Sung-Soo Park (2)  ·  Beijing GoBroad Hospital (1)  ·  Guangzhou Women and Children's Medical Center (1)  ·  M.D. Anderson Cancer Center (1)  ·  Mingzhi Zhang (1)  ·  Peking University People's Hospital (1)  ·  Zhao Weili (1)

Countries

China (9)  ·  South Korea (2)  ·  United States (1)

Top investigators

Hua Jiang, phd (1)  ·  Neeraj Saini, MD (1)  ·  Xiaojun Huang (1)

Results publications

PMID 39441941